Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed. Additionally, information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.7%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check43 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.9%
- Check72 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check86 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a proposed phase I/II study involving cabozantinib for treating relapsed/refractory multiple myeloma, while adding references to collaborators and a new version revision.SummaryDifference61%
Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.